KR102756637B1 - Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산 - Google Patents
Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산 Download PDFInfo
- Publication number
- KR102756637B1 KR102756637B1 KR1020207020557A KR20207020557A KR102756637B1 KR 102756637 B1 KR102756637 B1 KR 102756637B1 KR 1020207020557 A KR1020207020557 A KR 1020207020557A KR 20207020557 A KR20207020557 A KR 20207020557A KR 102756637 B1 KR102756637 B1 KR 102756637B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- amino
- lpa
- oxy
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607407P | 2017-12-19 | 2017-12-19 | |
| US62/607,407 | 2017-12-19 | ||
| PCT/US2018/066128 WO2019126099A1 (en) | 2017-12-19 | 2018-12-18 | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200100724A KR20200100724A (ko) | 2020-08-26 |
| KR102756637B1 true KR102756637B1 (ko) | 2025-01-16 |
Family
ID=65003584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207020557A Active KR102756637B1 (ko) | 2017-12-19 | 2018-12-18 | Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11447475B2 (https=) |
| EP (1) | EP3728210B1 (https=) |
| JP (1) | JP7301840B2 (https=) |
| KR (1) | KR102756637B1 (https=) |
| CN (1) | CN112041304B (https=) |
| ES (1) | ES3063964T3 (https=) |
| WO (1) | WO2019126099A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP4011875A1 (en) | 2017-12-19 | 2022-06-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| KR20220024549A (ko) * | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 카르복실산 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| JP2023505704A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としてのキナゾリン誘導体 |
| WO2021116259A1 (en) | 2019-12-12 | 2021-06-17 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| CN114746425A (zh) | 2019-12-12 | 2022-07-12 | 奇斯药制品公司 | 作为lpa受体2抑制剂的噻吩并嘧啶衍生物 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| WO2022013378A1 (en) | 2020-07-16 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| EP4670791A3 (en) * | 2020-10-22 | 2026-03-04 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
| CN114456157A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| JP2024512557A (ja) | 2021-03-24 | 2024-03-19 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
| EP4490150A1 (en) | 2022-03-08 | 2025-01-15 | Chiesi Farmaceutici S.p.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JP4692281B2 (ja) | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| US20140329871A1 (en) | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| UA109868C2 (ru) | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) |
| SG11201407228PA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-aryltriazole compounds as lpar antagonists |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP4011875A1 (en) | 2017-12-19 | 2022-06-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| US11180488B2 (en) * | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CN111699180B (zh) * | 2017-12-19 | 2024-11-29 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸 |
| KR102756639B1 (ko) * | 2017-12-19 | 2025-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸 |
-
2018
- 2018-12-18 US US16/954,550 patent/US11447475B2/en active Active
- 2018-12-18 JP JP2020533679A patent/JP7301840B2/ja active Active
- 2018-12-18 CN CN201880089219.XA patent/CN112041304B/zh active Active
- 2018-12-18 KR KR1020207020557A patent/KR102756637B1/ko active Active
- 2018-12-18 ES ES18830685T patent/ES3063964T3/es active Active
- 2018-12-18 EP EP18830685.6A patent/EP3728210B1/en active Active
- 2018-12-18 WO PCT/US2018/066128 patent/WO2019126099A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019126099A1 (en) | 2019-06-27 |
| EP3728210C0 (en) | 2026-02-11 |
| CN112041304A (zh) | 2020-12-04 |
| EP3728210B1 (en) | 2026-02-11 |
| KR20200100724A (ko) | 2020-08-26 |
| JP7301840B2 (ja) | 2023-07-03 |
| ES3063964T3 (en) | 2026-04-21 |
| CN112041304B (zh) | 2025-03-07 |
| US20200308157A1 (en) | 2020-10-01 |
| JP2021507896A (ja) | 2021-02-25 |
| US11447475B2 (en) | 2022-09-20 |
| EP3728210A1 (en) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102756637B1 (ko) | Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산 | |
| KR102828422B1 (ko) | Lpa 길항제로서의 시클로헥실 산 이속사졸 아진 | |
| KR102756639B1 (ko) | Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸 | |
| KR102702229B1 (ko) | Lpa 길항제로서의 트리아졸 n-연결된 카르바모일 시클로헥실 산 | |
| KR102697358B1 (ko) | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 | |
| KR102702231B1 (ko) | Lpa 길항제로서의 피라졸 o-연결된 카르바모일 시클로헥실 산 | |
| KR102698386B1 (ko) | Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산 | |
| KR102950123B1 (ko) | Lpa 길항제로서의 시클로펜틸 산 | |
| KR102791678B1 (ko) | Lpa 길항제로서의 시클로부틸 카르복실산 | |
| KR102725744B1 (ko) | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 | |
| KR102726939B1 (ko) | Lpa 길항제로서의 시클로헥실 산 피라졸 아졸 | |
| KR102800284B1 (ko) | Lpa 길항제로서의 시클로헵틸 산 | |
| KR102788997B1 (ko) | Lpa 길항제로서의 옥사비시클로 산 | |
| KR20220024549A (ko) | Lpa 길항제로서의 이속사졸 카르복실산 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200715 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211216 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240207 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241015 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250114 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250114 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |